IL283923B2 - 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof - Google Patents

3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof

Info

Publication number
IL283923B2
IL283923B2 IL283923A IL28392321A IL283923B2 IL 283923 B2 IL283923 B2 IL 283923B2 IL 283923 A IL283923 A IL 283923A IL 28392321 A IL28392321 A IL 28392321A IL 283923 B2 IL283923 B2 IL 283923B2
Authority
IL
Israel
Prior art keywords
anatabine
glutarate
tetrahydropyridin
pyridine
polymorphic form
Prior art date
Application number
IL283923A
Other languages
English (en)
Hebrew (he)
Other versions
IL283923A (en
IL283923B1 (en
Original Assignee
Philip Morris Products Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products Sa filed Critical Philip Morris Products Sa
Publication of IL283923A publication Critical patent/IL283923A/en
Publication of IL283923B1 publication Critical patent/IL283923B1/en
Publication of IL283923B2 publication Critical patent/IL283923B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL283923A 2018-12-17 2019-12-17 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof IL283923B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18213200 2018-12-17
PCT/EP2019/085598 WO2020127225A1 (en) 2018-12-17 2019-12-17 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof

Publications (3)

Publication Number Publication Date
IL283923A IL283923A (en) 2021-07-29
IL283923B1 IL283923B1 (en) 2025-04-01
IL283923B2 true IL283923B2 (en) 2025-08-01

Family

ID=64744512

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283923A IL283923B2 (en) 2018-12-17 2019-12-17 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof

Country Status (20)

Country Link
US (2) US12281093B2 (pl)
EP (1) EP3898607B1 (pl)
JP (1) JP2022514283A (pl)
KR (1) KR20210104666A (pl)
CN (1) CN113039180A (pl)
AU (1) AU2019407661B2 (pl)
BR (1) BR112021009580A2 (pl)
CA (1) CA3116524A1 (pl)
CL (1) CL2021001583A1 (pl)
CO (1) CO2021009186A2 (pl)
EC (1) ECSP21052586A (pl)
ES (1) ES2964561T3 (pl)
HU (1) HUE063731T2 (pl)
IL (1) IL283923B2 (pl)
MX (1) MX2021006867A (pl)
PH (1) PH12021550875A1 (pl)
PL (1) PL3898607T3 (pl)
UA (1) UA128729C2 (pl)
WO (1) WO2020127225A1 (pl)
ZA (1) ZA202102058B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12594238B2 (en) * 2020-09-03 2026-04-07 Philip Morris Products S.A. Low hygroscopicity active powder compositions
BR112023003114A2 (pt) 2020-09-03 2023-04-04 Philip Morris Products Sa Composições em pó ativas de baixa higroscopicidade liofilizadas
WO2022049488A1 (en) 2020-09-03 2022-03-10 Philip Morris Products S.A. Spray dried low hygroscopicity active powder compositions
KR20230129258A (ko) * 2021-01-07 2023-09-07 필립모리스 프로덕츠 에스.에이. 아나타빈을 포함하는 조성물 및 이의 용도
CN118924725B (zh) * 2024-09-09 2025-11-21 中国农业大学 3,3-二甲基戊二酸在制备治疗自闭症谱系障碍产品中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119722A2 (en) * 2010-03-23 2011-09-29 Rock Creek Pharmaceuticals, Inc. Use of anatabine to treat inflammation and methods of synthesizing anatabine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5942244A (en) 1997-07-31 1999-08-24 Farmo-Nat Ltd. Local oral herbal slow release tablets
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CN2719043Y (zh) 2004-04-14 2005-08-24 韩力 雾化电子烟
US8207346B2 (en) 2010-03-23 2012-06-26 Rock Creek Pharmaceuticals, Inc. Methods of synthesizing anatabine
US8241680B2 (en) 2010-06-30 2012-08-14 Rock Creek Pharmaceuticals, Inc. Nutraceutical product containing anatabine and yerba maté
US20120245202A1 (en) * 2010-09-17 2012-09-27 Rock Creek Pharmaceuticals, Inc. Methods and products for treating inflammation
US20120325228A1 (en) 2011-06-23 2012-12-27 Williams Jonnie R Alkaloid composition for e-cigarette
WO2013032558A2 (en) 2011-08-29 2013-03-07 Rock Creek Pharmaceuticals, Inc. Products for anti-inflammation support
WO2015009500A1 (en) 2013-07-19 2015-01-22 Williams Jonnie R Volatilized delivery of anatabine for treatment of substance addiction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119722A2 (en) * 2010-03-23 2011-09-29 Rock Creek Pharmaceuticals, Inc. Use of anatabine to treat inflammation and methods of synthesizing anatabine

Also Published As

Publication number Publication date
US20210395218A1 (en) 2021-12-23
CA3116524A1 (en) 2020-06-25
ECSP21052586A (es) 2021-08-31
AU2019407661B2 (en) 2024-07-25
ZA202102058B (en) 2022-09-28
CL2021001583A1 (es) 2021-11-26
PH12021550875A1 (en) 2021-10-18
US12281093B2 (en) 2025-04-22
EP3898607C0 (en) 2023-10-18
PL3898607T3 (pl) 2024-03-18
ES2964561T3 (es) 2024-04-08
KR20210104666A (ko) 2021-08-25
JP2022514283A (ja) 2022-02-10
WO2020127225A1 (en) 2020-06-25
CO2021009186A2 (es) 2021-08-30
EP3898607B1 (en) 2023-10-18
EP3898607A1 (en) 2021-10-27
AU2019407661A1 (en) 2021-04-29
UA128729C2 (uk) 2024-10-09
IL283923A (en) 2021-07-29
BR112021009580A2 (pt) 2021-08-17
CN113039180A (zh) 2021-06-25
MX2021006867A (es) 2021-07-02
IL283923B1 (en) 2025-04-01
HUE063731T2 (hu) 2024-01-28
US20250243178A1 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
US20250243178A1 (en) 3-(1,2,3,6-tetrahydropyridin-2-yl) pyridine glutarate or a pharmaceutically acceptable solvate thereof
CN116761599B (zh) 氘代或部分氘代的n,n-二甲基色胺化合物
TWI831325B (zh) 作為atr抑制劑的萘啶衍生物及其製備方法
CA2900322C (en) Solid forms of the selective cdk4/6 inhibitor compound acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one
CA2741575C (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
TW202334165A (zh) Irak4降解劑及其製備
ES2869851T3 (es) Uso de la anatabina para tratar la inflamación y métodos de síntesis de anatabina
CN108699084A (zh) 取代全氢吡咯并[3,4-c]吡咯衍生物及其用途
CA3031136A1 (en) Substituted imidazo[1,2-a]pyridin-3-yl compounds and their use for the treatment and/or prevention of respiratory disorders
CN101284812A (zh) 他克林-阿魏酸杂联体,其制备方法及其药物组合物
JP6174695B2 (ja) ホスホジエステラーゼ１０酵素の阻害剤
CA3260633A1 (en) POLYMORPHIC COMPOUNDS AND THEIR USES
RU2823979C2 (ru) Глутарат 3-[1,2,3,6-тетрагидропиридин-2-ил]пиридина или его фармацевтически приемлемый сольват
HK40052039A (en) 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof
HK40052039B (en) 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof
CN109843300B (zh) 一种化合物的结晶多晶型形式
CN114507153B (zh) 一类间苯二酚化合物及其制备方法以及在神经系统疾病中的应用
UA72631C2 (uk) Кристалічний терапевтичний агент
US20250268910A1 (en) Nicotinic acetylcholine receptor ligands
ES3005357T3 (en) Use of anatabine for reducing blood serum levels of c-reactive protein in an individual
WO2025184565A1 (en) Targeted protein modification
NZ716165B2 (en) 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS